(Q53631355)

16 May 2018

title

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. (English)

1 reference

16 May 2018

1 reference

1 reference

5

Laura J Havrilesky

1 reference

16 May 2018

Angeles Alvarez Secord

2

Angeles Alvarez Secord

1 reference

16 May 2018

Kathleen M Darcy

4

Kathleen M Darcy

1 reference

16 May 2018

Gynecologic Oncology Group

1

Gynecologic Oncology Group

1 reference

16 May 2018

Andrew Berchuck

8

Andrew Berchuck

1 reference

16 May 2018

Lisa A Grace

6

Lisa A Grace

1 reference

16 May 2018

author name string

Paula S Lee

3

1 reference

16 May 2018

Jeffrey R Marks

7

1 reference

16 May 2018

language of work or name

English

0 references

publication date

21 March 2006

1 reference

16 May 2018

published in

Gynecologic Oncology

1 reference

16 May 2018

volume

101

1 reference

16 May 2018

issue

3

1 reference

16 May 2018

page(s)

390-397

1 reference

16 May 2018

Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Maspin--a novel protease inhibitor with tumor-suppressing activity in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Maspin is an angiogenesis inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Expression of maspin predicts poor prognosis in breast-cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Gene expression profiles in human gastric cancer: expression of maspin correlates with lymph node metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Expression of maspin in prostate cells is regulated by a positive ets element and a negative hormonal responsive element site recognized by androgen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Epigenetic silencing of maspin gene expression in human breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

De-mystifying the mechanism(s) of maspin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

p53 regulates the expression of the tumor suppressor gene maspin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Methylation matters: a new spin on maspin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

DNA methylation and breast carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Aberrant methylation of the maspin promoter is an early event in human breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Maspin expression in invasive breast cancer: association with other prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Stage III epithelial ovarian cancer: the role of maximal surgical reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Prognostic factors in advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.014

10.1016/J.YGYNO.2006.02.014

7 January 2021

Identifiers

DOI

1 reference

16 May 2018

1 reference

16 May 2018